Cholinesterase Inhibitors in the Clinical Management of Alzheimer's Disease: Importance of Early and Persistent Treatment
Author:
- 1 August 2006
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 34 (4) , 339-347
Abstract
Alzheimer's disease is a neurodegenerative disease that greatly affects the quality of life of patients and their caregivers and places a heavy cost burden on the healthcare system. The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine have a central role in the treatment of Alzheimer's disease in the mild to moderate stages. Clinical trials with ChEIs have demonstrated therapeutic benefits for symptoms of cognition, function and behaviour across the disease course. These agents are most effective when started early in the disease course and used persistently, without treatment gaps. Early recognition of Alzheimer's disease and a global evaluation of treatment effectiveness are therefore essential. This article identifies barriers to early recognition and effective care of patients with Alzheimer's disease and discusses practical strategies to overcome them.Keywords
This publication has 38 references indexed in Scilit:
- Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer’s DiseaseAmerican Journal of Psychiatry, 2004
- Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s DiseaseAmerican Journal of Psychiatry, 2003
- Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical NeuronsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver BurdenJournal of the American Geriatrics Society, 2003
- Cerebral glucose metabolism, cerebrospinal fluid-β-amyloid1–42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patientsNeuroscience Letters, 2003
- Cost-Effective Recognition and Diagnosis of DementiaSeminars in Neurology, 2002
- Changes in the rCBF images of patients with Alzheimerʼs disease receiving Donepezil therapyNuclear Medicine Communications, 2000
- The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1Dementia and Geriatric Cognitive Disorders, 1999
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982